All In Biotech

Drug Trial Radar · NCT07826767

Open-label Gene Therapy Study in p47-CGD

An Open-label, Single-arm, Phase 1/2 First-in-human Study to Assess the Safety and Efficacy of Autologous CD34+ Cells Transduced With a Lentiviral Vector Encoding the Human NCF1 Gene (SGX-001) in Paediatric and Adult Patients With Chronic Granulomatous Disease Caused by p47phox Deficiency

Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

5

Planned (sponsor's estimate)

Start

Aug 18, 2026

Primary completion

Jul 2028

Study completion Sep 2028

Sponsor

Lead sponsor
Somagenetix AGIndustry
Sponsor type
Industry
First posted
Sep 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Chronic granulomatous disease (CGD) caused by p47phox deficiency (p47-CGD) is a life-threatening genetic disorder causing nicotinamide adenine dinucleotide phosphate (NADPH) oxidase deficiency in phagocytes. This leads to severe bacterial and fungal infections as well as hyperinflammatory complications that significantly reduces life expectancy. Standard of care includes daily antimicrobial prophylactic treatment by conventional pharmacotherapy. This aims to prevent or reduce the frequency and severity of infections and other disease manifestations. However, the underlying genetic defect in neutrophil cytosolic factor 1 (NCF1) cannot be cured by pharmacotherapy, and many p47-CGD patients suffer from significant morbidity, impaired quality of life, and early mortality. Allogeneic haematopoietic stem cell transplant (HSCT), the only established curative treatment and carries substantial risks when using non-sibling donors. Risks include graft failure and graft-versus-host disease. Treatment with SGX-001 aims to cure the underlying genetic defect using autologous haematopoietic stem and progenitor cells (HSPCs) transduced with a lentiviral self-inactivating vector to express transgenic p47phox protein and restore NADPH oxidase function in phagocytes. This treatment eliminates the need for allogeneic HSCT and could offer a safer alternative to allogeneic transplantation for patients without ideal donors. In this study, safety and efficacy of SGX-001 will be investigated in participants with p47-CGD who have an indication for allogeneic HSCT but lack a human leukocyte antigen-matched suitable sibling donor.

Conditions

  • Chronic Granulomatous Disease (CGD)

Interventions

  • SGX-001Biological

    Autologous CD34+ cell-enriched population that contains HSPCs transduced with a lentiviral vector encoding the human NCF1 gene

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of safety events following a single administration of SGX-001Time frame: 12 months
  2. Number of participants with a response to SGX-001 based on NADPH oxidase activity in peripheral blood granulocytesTime frame: 12 months

Locations

3 sites in 3 countries. Site status is shown where the registry gives one.

  • Universitaetsklinikum Ulm

    Ulm, Germany · Not yet recruiting

  • Hospital Universitari Vall D Hebron

    Barcelona, Spain · Not yet recruiting

  • University Children's Hospital Zurich

    Zurich, Switzerland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.